Icatibant
Icatibant is an FDA-approved bradykinin B2 receptor antagonist. Attacks of hereditary angioedema are driven by excess bradykinin acting at the B2 receptor on vascular endothelium, which increases permeability and causes plasma extravasation into subcutaneous and submucosal tissue. Icatibant is a synthetic decapeptide containing five non-proteinogenic amino acids that competitively blocks the B2 receptor, halting that signal.
For research use only.
Key Facts
- CAS
- 130308-48-4
- Molecular Weight (MW)
- 1304.5 g/mol
- Half-life
- —
- FDA status
- Approved
- Administration Route
- subcutaneous
- Frequency
- —
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
Research summary
Selective bradykinin B2 receptor antagonist approved for acute attacks of hereditary angioedema in adults and adolescents. It can be self-administered.
Peptide Library's Icatibant profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- —
- Frequency
- —
- Cycle
- —
- Administration Route
- subcutaneous
- Reconstitution Guide
- —
Sequence & molecular data
| Molecular formula | C59H89N19O13S |
|---|---|
| Molecular weight | 1304.5 g/mol |
| CAS number | 130308-48-4 |
| PubChem CID | 6918173 |
| FDA UNII | 7PG89G35Q7 |
| ChEMBL | CHEMBL2028850 |
| DrugBank | DB06196 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Attacks of hereditary angioedema are driven by excess bradykinin acting at the B2 receptor on vascular endothelium, which increases permeability and causes plasma extravasation into subcutaneous and submucosal tissue. Icatibant is a synthetic decapeptide containing five non-proteinogenic amino acids that competitively blocks the B2 receptor, halting that signal. The unnatural residues make it resistant to peptidase degradation.
Regulatory & research status
Icatibant is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Research status | Approved product (see FDA status) |
| Availability | Prescription-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | FDA-Approved |
Benefits
—
Potential Side Effects
No side effects listed yet for this entry.
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Icatibant: frequently asked questions
What is Icatibant?
Selective bradykinin B2 receptor antagonist approved for acute attacks of hereditary angioedema in adults and adolescents. It can be self-administered.
How does Icatibant work?
Attacks of hereditary angioedema are driven by excess bradykinin acting at the B2 receptor on vascular endothelium, which increases permeability and causes plasma extravasation into subcutaneous and submucosal tissue. Icatibant is a synthetic decapeptide containing five non-proteinogenic amino acids that competitively blocks the B2 receptor, halting that signal.
Is Icatibant FDA approved?
Yes. Icatibant is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What peptides are similar to Icatibant?
Compounds most often compared with Icatibant include Angiotensin II, Cetrorelix, Corticorelin and Cosyntropin. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Efficacy of Treatment of Non-hereditary Angioedema — Clin Rev Allergy Immunol, 2018External reference
- Icatibant for hereditary angioedema — Drugs Today (Barc), 2009External reference
- Therapeutic potential of icatibant (HOE-140, JE-049) — Expert Opin Pharmacother, 2008External reference
- Icatibant, 2006External reference
- First reported case of Andes hantavirus cardiopulmonary syndrome treated with a combination of favipiravir, ribavirin, icatibant and baricitinib — Clin Microbiol Infect, 2026External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Icatibant profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Icatibant research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →